Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Cao, Xun ^a,b   Zhang, Lin ^a,c   Feng, Gui Rong ^a,b   Yang, Juan ^a,c   Wang, Ruo Yan ^a,b   Li, Jun ^d   Zheng, Xiao Min ^a,b   Han, Yu Jing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Thoracic Oncology ^*  (China)

^c Clincal Laboratory   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cyfra21 1; Esophageal squamous cell carcinoma; Prognosis; SCC Ag

Indexed keywords

CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SURVIVAL PREDICTION; SURVIVAL RATE;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-19; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERPINS;

EID: 84866497960     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-197     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Ke L. Mortality and incidence trends from esophagus cancer inselected geographic areas of China circa 1970-90. Int J Cancer 2002, 102(3):271-274. 10.1002/ijc.10706, 12397650.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252. 10.1056/NEJMra035010, 14657432.
4. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000, 190(5):562-572. discussion 572-563, 10.1016/S1072-7515(00)00238-6, 10801023.
5. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996, 224(1):66-71. 10.1097/00000658-199607000-00010, 1235248, 8678620.
6. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy?. Ann Thorac Surg 1992, 54(2):199-204. 10.1016/0003-4975(92)91370-O, 1637206.
7. Headrick JR, Nichols FC, Miller DL, Allen MS, Trastek VF, Deschamps C, Schleck CD, Thompson AM, Pairolero PC. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002, 73(6):1697-1702. discussion 1702-1693, 10.1016/S0003-4975(02)03496-3, 12078755.
8. Reed CE. Surgical management of esophageal carcinoma. Oncologist 1999, 4(2):95-105.
9. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008, 15(2):583-589. 10.1245/s10434-007-9650-y, 17955299.
10. Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, Felip E. Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer 2011, 12(3):172-179. 10.1016/j.cllc.2011.03.019, 21663860.
11. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006, 107(12):2842-2849. 10.1002/cncr.22330, 17103443.
12. Catanzaro JM, Guerriero JL, Liu J, Ullman E, Sheshadri N, Chen JJ, Zong WX. Elevated expression of squamous cell carcinoma antigen (SCCA) is associated with human breast carcinoma. PLoS One 2011, 6(4):e19096. 10.1371/journal.pone.0019096, 3079753, 21526154.
13. Olsen JR, Dehdashti F, Siegel BA, Zighelboim I, Grigsby PW, Schwarz JK. Prognostic Utility of Squamous Cell Carcinoma Antigen in Carcinoma of the Cervix: Association with Pre- and Posttreatment FDG-PET. Int J Radiat Oncol Biol Phys 2010, 81(3):772-777.
14. Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, Pontisso P, Saetta M, Valente M, Rea F, Perissinotto E, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax 2008, 63(9):795-802. 10.1136/thx.2007.088583, 18344408.
15. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010, 17(7):1721-1724. 10.1245/s10434-010-1024-1, 20369299.
16. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, et al. Extended transthoracic resection compared with limited transhiatal resectionfor adenocarcinoma of the esophagus. N Engl J Med 2002, 347(21):1662-1669. 10.1056/NEJMoa022343, 12444180.
17. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993, 80(3):367-370. 10.1002/bjs.1800800335, 8472154.
18. Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, Greenberg AK, Rom WN, Brenner DE, Omenn GS, Haab BB, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005, 5:110. 10.1186/1471-2407-5-110, 1198221, 16117833.
19. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Jelski W, Laudanski J, Chyczewski L, Szmitkowski M. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta 2008, 389(1-2):61-66.
20. Khan N, Cromer CJ, Campa M, Patz EF. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkersfor the detection of nonsmall cell lung carcinoma. Cancer 2004, 101(2):379-384. 10.1002/cncr.20377, 15241837.
21. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995, 13(2):169-176. 10.1016/0169-5002(95)00485-8, 8581396.
22. Tanaka K, Yano M, Motoori M, Kishi K, Miyashiro I, Shingai T, Gotoh K, Noura S, Takahashi H, Ohue M, et al. CEA-antigen and SCC-antigen mRNA expression in peripheral blood predict hematogenous recurrence after resection in patients with esophageal cancer. Ann Surg Oncol 2010, 17(10):2779-2786. 10.1245/s10434-010-1075-3, 20411433.
23. Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996, 22(5):505-507. 10.1016/S0748-7983(96)92998-4, 8903494.
24. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, et al. New consensus nomenclature for mammalian keratins. J Cell Biol 2006, 174(2):169-174. 10.1083/jcb.200603161, 2064177, 16831889.
25. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006, 13(4):1033-1067. 10.1677/ERC-06-0001, 17158753.
26. Chang CC, Yang SH, Chien CC, Chen SH, Pan S, Lee CL, Lin CM, Sun HL, Huang CC, Wu YY, et al. Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer 2009, 9:376. 10.1186/1471-2407-9-376, 2776602, 19849844.
27. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009, 101(4):589-597. 10.1038/sj.bjc.6605183, 2736820, 19623181.
28. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009, 27(13):2177-2184. 10.1200/JCO.2008.18.0497, 19332733.
29. Kosacka M, Jankowska R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn 2009, 119(1-2):33-37.
30. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40(4):1621-1628. 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I, 332328.
31. Mino N, Iio A, Hamamoto K. Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer 1988, 62(4):730-734. 10.1002/1097-0142(19880815)62:4<730::AID-CNCR2820620415>3.0.CO;2-W, 2840187.
32. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A. CYFRA 21-1. A new marker in lung cancer. Cancer 1993, 72(3):707-713. 10.1002/1097-0142(19930801)72:3<707::AID-CNCR2820720313>3.0.CO;2-X, 7687515.
33. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Takenoyama M, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011, 74(1):112-117. 10.1016/j.lungcan.2011.02.001, 21397974.
34. Shi J, Sugrue SP. Dissection of protein linkage between keratins and pinin, a protein with dual location at desmosome-intermediate filament complex and in the nucleus. J Biol Chem 2000, 275(20):14910-14915. 10.1074/jbc.275.20.14910, 10809736.
35. Suminami Y, Nawata S, Kato H. Biological role of SCC antigen. Tumour Biol 1998, 19(6):488-493. 10.1159/000030042, 9817978.
36. Yoon SM, Shin KH, Kim JY, Seo SS, Park SY, Moon SH, Cho KH. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy. Radiat Oncol 2010, 5:78. 10.1186/1748-717X-5-78, 2949677, 20840788.